I've checked some of my replies to you and unless you brought up "the other MSC" company, neither did I. Unlike other posters, you use the same measures when evaluating the two (mostly anyway), hence I don't see a need to point out similar incidences that are hailed as wonders one one side, and failures on the other. I think we agree that this is rather a case of "who stuffed up worse" at this stage.
Neither of the two should have seen the recent low SPs.
Sure, next 4C, I'll be here, also with a "%" update on patient recruitment in the P2 trial.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.5¢ | 16.0¢ | $10.82K | 65.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4450 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 88474 | 2 |
View Market Depth
| Last trade - 15.32pm 20/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |